Kelly A. Romano
Kelly A. Romano's purchase track record
How the stock did after each of Kelly A. Romano's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/21/2024 | LONA | $100K | -81.6% | -75.4% | +8.5% |
| 12/2/2022 | LONA | $99K | -4.6% | -7.9% | +5.2% |
| 3/31/2022 | LONA | $105K | -77.4% | -77.3% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Scotiabank initiates UGI coverage with Sector Outperform rating. Scotiabank began tracking UGI with a Sector Outperform rating and a $46 price target. This follows a regulatory decision allowing phased gas rate increases while blocking a base-rate filing until 2029. The new analyst view provides a fresh perspective on the utility's valuation and regulatory outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
LeonaBio appears among health‑care stocks moving intraday. LeonaBio was listed among twelve health‑care stocks that showed notable price movement on Monday and again on Friday, according to Benzinga. The mentions suggest the stock experienced intraday volatility during those sessions. With the RSI currently low and the price near a recent support level, the recent activity aligns with a broader sector‑wide movement.
Transaction History
| DORM | ▲ Buy | Grant | 1,344 | $165K | 6/1/2026 | View on chart |
| DORM | ▼ Sell | Tax Withholding | 33 | $4K | 5/15/2026 | View on chart |
| UGI | ▲ Buy | Grant | 4,364 | $0 | 1/30/2026 | View on chart |
| DORM | ▲ Buy | Grant | 1,070 | $0 | 6/2/2025 | View on chart |
| DORM | ▼ Sell | Tax Withholding | 46 | $6K | 5/16/2025 | View on chart |
| UGI | ▲ Buy | Grant | 5,695 | $0 | 1/31/2025 | View on chart |
| LONA | ▲ Buy | Open Market | 27,400 | $66K | 6/24/2024 | View on chart |
| LONA | ▲ Buy | Open Market | 15,000 | $34K | 6/21/2024 | View on chart |
| DORM | ▲ Buy | Grant | 1,471 | $0 | 6/3/2024 | View on chart |
| DORM | ▼ Sell | Tax Withholding | 47 | $4K | 5/17/2024 | View on chart |
| UGI | ▲ Buy | Grant | 4,470 | $0 | 1/26/2024 | View on chart |
| DORM | ▲ Buy | Grant | 1,510 | $0 | 6/1/2023 | View on chart |
| DORM | ▼ Sell | Tax Withholding | 38 | $3K | 5/18/2023 | View on chart |
| UGI | ▲ Buy | Grant | 2,600 | $0 | 1/27/2023 | View on chart |
| LONA | ▲ Buy | Open Market | 30,000 | $99K | 12/2/2022 | View on chart |
| DORM | ▲ Buy | Grant | 1,223 | $0 | 6/1/2022 | View on chart |
| DORM | ▼ Sell | Tax Withholding | 33 | $3K | 5/25/2022 | View on chart |
| LONA | ▲ Buy | Open Market | 8,000 | $105K | 3/31/2022 | View on chart |
| UGI | ▲ Buy | Grant | 6,050 | $0 | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dorman Products Sets Date for Q3 2026 Earnings Report
Dorman Products has announced the date it will release its third-quarter 2026 financial results. This announcement provides investors with a specific timeline to monitor upcoming performance metrics. The company's stock is currently trading below its average analyst target price.
Dorman Products Sets Date for Q3 2026 Earnings Report. Dorman Products has announced the date it will release its third-quarter 2026 financial results. This announcement provides investors with a specific timeline to monitor upcoming performance metrics. The company's stock is currently trading below its average analyst target price.